Aurobindo Pharma Announcements
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral...
17 Apr, 2026 | 11:07am • Source: NSE
Submission of Press Release that is being issued by the Company in connection with receipt of US FDA approval for Glycerol Phenylbutyrate Oral liquid.
17 Apr, 2026 | 10:37am • Source: BSE
Submission of compliances certificate under Reg.74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31..03.2026.
09 Apr, 2026 | 04:20pm • Source: BSE
Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers and Board Resolution.
08 Apr, 2026 | 04:23pm • Source: BSE
Submission of Public Announcement pertaining to Buyback of shares of the Company published in newspapers
08 Apr, 2026 | 04:07pm • Source: BSE
Submission of Press Release on receipt of USFDA approval for Dapagliflozin and Metformin Hydrochloride Extended-Release tablets.
07 Apr, 2026 | 06:29pm • Source: BSE
Submission of press release on receipt of USFDA approval for Dapagliflozin Tablets. 5 mg and 10 mg.
07 Apr, 2026 | 06:24pm • Source: BSE
Submission of Press Release.
06 Apr, 2026 | 04:04pm • Source: BSE
Intimation of April 17, 2026 as the record date for buy back of the Company.
06 Apr, 2026 | 08:51am • Source: BSE
Intimation of transfer of Company''s domestic branded pharmaceutical formulation business to Auropharm Limited, a wholly owned subsidiary of the Company.
06 Apr, 2026 | 08:35am • Source: BSE
The Board of the Aurobindo Pharma Limited at its meeting held today (i.e., April 6, 2026), has inter-alia, considered and approved subject to such...
06 Apr, 2026 | 08:24am • Source: BSE
Submission of update on solar power purchase agreement and acquisition of 26% stake in Swarnaakshu Solar Power Private Limited.
30 Mar, 2026 | 05:36pm • Source: BSE
Submission of Postal Ballot Results and Scrutinizers Report
30 Mar, 2026 | 12:05pm • Source: BSE
Intimation of entry into marketing and distribution agreement for Biosimilars in EU territories by Curateq Biologics Private Limited, a wholly owned subsidiary of the Company.
25 Mar, 2026 | 04:53pm • Source: BSE
Intimation of closure of Trading Window
23 Mar, 2026 | 05:44pm • Source: BSE
Intimation of classification of Unit-V of Apitoria Pharma Private Limited , a wholly owned subsidiary of the Company as VAI by the US FDA.
20 Mar, 2026 | 09:57am • Source: BSE
Aurobindo Pharma Limited has informed the Exchange about General Updates
12 Mar, 2026 | 11:01am • Source: NSE
Intimation of classification of Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the Company as VAI by the US FDA.
12 Mar, 2026 | 09:44am • Source: BSE
Intimation of plant visit by a group of investors on 17.03.2026.
11 Mar, 2026 | 01:14pm • Source: BSE